Risk adjusted net present value: What is the current valuation of Medivir’s Fostroxacitabine Bralpamide Hydrochloride?

Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.

Adjusting forecast for the current fiscal year – Biotech Investments

MeVis Medical Solutions AG / Key word(s): Change in Forecast MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year 31-Jul-2023 / 16:27 CET/CEST

August 1, 2023

Turning wine waste into wellness: Grape pomace’s journey from by-product to superfood

A study in Foods highlights grape pomace’s (GP) potential in preventing winery waste, showcasing its bioactive properties for health benefits and applications in food and

February 16, 2024

Psychedelic Halloween: Shopping Guide for Psychonauts | Psychedelic Spotlight

Boo! Did we catch you off guard? Good, because this Halloween, we’re pushing the boundaries to give you a psychedelic Halloween like no other! Time

September 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.